NSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,294.80
- Market cap
- ₹5,963 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 47.2×Sector 46.1×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
- Value
- ₹95.00 Cr
Senores Pharmaceuticals Capacity Expansion: ₹20 Cr Investment
Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited plans a 0.7 Bn unit capacity addition by March 2027. The investment is Rs.20.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹20.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.7 Bn units
Senores Pharmaceuticals Capacity Expansion: ₹18 Cr Investment
Senores Pharmaceuticals plans to add 0.8 Bn units of capacity to its existing 1.2 Bn unit plant by March 2027. The investment is Rs.18.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹18.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.8 Bn units
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Senores Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Senores Pharmaceuticals Results Update
Senores reported Q2 FY27 revenue of ₹192 cr and EBITDA of ₹58 cr, both record highs. PAT grew 22% Y-o-Y to ₹37 cr with positive FY27 outlook.
Other management change announcements
All →Apar Industries Management Change
APAR Industries re-appointed Mr. Kaushal J. Sampat as Non-Executive Independent Director for a second 5-year term from 31 January 2027. Subject to shareholder approval.
- Execution
- 60 months
The Ravalgaon Sugar Farm Management Change
Ravalgaon Sugar Farm re-appointed Sandesh Kadam & Associates as internal auditor and S. R. Padhye & Co. as secretarial auditor. It also appointed Maahi Amit Ahuja as Company Secretary and Compliance Officer effective 1 December 2026.
Tokyo Plast International Management Change
Tokyo Plast International appointed Ms. Ayushi Deepak Doshi as Company Secretary and Compliance Officer, a KMP, effective 29 October 2026. The intimation lists her credentials and states no director relationships.
Globus Power Generation Management Change
Globus Power Generation appointed Devesh Bhargava as Independent Director for five years, subject to shareholder approval. Thamattoor Prabhakaran Nair resigned as Independent Director effective 30 October 2026.
- Execution
- 5 years (29 Oct 2026 to 28 Oct 2031)
Meesho Management Change
Meesho appointed Sudhir Ganesh Sitapati as Additional Non-Executive Independent Director for 60 months, effective 28 October 2026. He is a former Godrej Consumer Products MD and CEO.
Aplab Management Change
APLAB Limited appointed Rakesh Margam as Company Secretary and Compliance Officer, effective 29 October 2026. The change is a senior management appointment with no financial impact.